EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 antibody-drug conjugate EGFR and HER3 ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed ...

MabGenesis, a biotechnology company specializing in antibody drug development, announced on the 24th that it has raised 470 million yen (approximately $3.2 million) in its latest funding round.

INR:6695. rummy 9999 Johnson & Johnson's EGFR-MET dual antibody registration starts first-line non-small cell lung cancer Phase III clinical trial Medical equipment co ...

Magnum opus synonym Bristol-Myers Squibb and others reach collaboration to develop innovative “synthetic lethal” precision medicine Johnson & Jo ...